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The increased survival of very preterm infants is generally attributed to improved 
care strategies. This review develops the thesis that the features of abnormal preg-
nancies responsible for very preterm deliveries also provide an explanation of why 
very preterm infants often survive. A normal fetus born at 24 weeks is very unlikely 
to survive. However, pregnancies that result in deliveries at 24 weeks are generally 
highly abnormal, and may have been so for prolonged periods prior to the preterm 
deliveries. Inflammatory or vascular developmental abnormalities resulting in very 
preterm birth can alter fetal development in such a way that organ system maturation 
is induced. This is supported clinically by the relative lack of very preterm infants 
with respiratory distress syndrome. Interventions such as antenatal corticosteroid 
treatment and postnatal surfactant treatment for infants with respiratory distress 
syndrome and gentle ventilation strategies maximize fetal adaptations to the 
abnormal fetal environment and improve outcomes.
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1.  Introduction
In the recent past, the survival of infants with birth 
weights less than 1000 g or with gestational ages of 
28 weeks or less was the exception. However, in 
societies that deliver advanced medical care, the 
survival of infants born at 28 weeks’ gestation is 
now approximately 90−95% of live births.1 Infants 
with a gestational age of 24 weeks have survival 
rates of 50%, and where systematic efforts are made 
to salvage more immature infants, remarkable survi-
vals have been reported.2 The medical community 
and the popular press have promoted this success 
in neonatal care as a medical miracle, implying that 
the progress is the result of interventional techniques 
by neonatal care providers. However, this review 
discusses the survival of these very immature infants 
from the biological perspective, often with quite 
modest support from care providers. The clinical 
information suggests that the miracle of survival 
can be explained by the biological adaptability/
plasticity of the very premature infant.
2.  The “Normal” 24-Week Gestation 
Fetus
Assuming a normal pregnancy, a 24-week gestation 
fetus weighs about 700 g and will have completed 
22 weeks (i.e., 58%) of the full period of fetal de-
velopment (24 weeks’ postmenstrual age equates 
to about 22 weeks’ fetal age). The fetus is thus 
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extremely immature in many respects. The fetal 
lung completes branching of the 16 generations of 
conducting airways by about 18 weeks and develops 
respiratory bronchioles that terminate in around 
240,000 saccules at 24 weeks.3 The tissues defin-
ing the potential air-blood barrier are thicker than 
at term and pulmonary microvascular development 
has not fully vascularized the saccular mesenchyme. 
The enzymes and lamellar bodies required for sur-
factant synthesis and secretion are just appearing 
as some type II cells begin to mature. A normal 
fetus at this age is completely surfactant deficient 
and unable to quickly synthesize or secrete surfactant 
if delivered. The fetal lung actively secretes fetal 
lung fluid and has not developed the ion pumps or 
lymphatics that assist with the clearance of fetal 
lung fluid. From the injury perspective, the lungs 
also contain very little collagen or elastin matrix 
to modulate stretch mediated injuries.4 The lung 
of the “normal” fetus at this age is not ready to 
support air breathing.
This fetus also has multiple other organ imma-
turities that only become “abnormalities” if the 
fetus is delivered (Table 1). These include kidneys 
with very low blood flow, low glomerular filtration 
rates, low tubular sodium reabsorption, and an in-
ability to concentrate urine. The gut has not devel-
oped the normal complement of digestive enzymes 
and peristalsis is not functioning normally. The skin 
is minimally cornified, which would result in ex-
cessive fluid loss, heat loss, and poor barrier func-
tion. The brain has not developed good respiratory 
control, and the immune system is naïve, antibody-
deficient and poorly responsive to infection. Any 
one of these organ systems inadequacies can result 
in death following preterm birth, and a normal fetus 
at 24-weeks gestation has simultaneous inadequa-
cies in all these systems. Despite these facts, many 
fetuses delivered prematurely at 24 weeks’ post-
menstrual age can survive. The current issue at-
tempts to address the why or how this has become 
possible.
3.  The Concept of the “Normal” Fetus
The normal fetus will not deliver until term. However, 
the most abnormal fetuses are those that deliver 
as preterms and survive at the margins of viability. 
Recent research into the causes of severe prema-
turity suggests that there are two main causes of 
severe prematurity: infection/inflammation, and 
abnormal vascular/placental development.5 These 
abnormalities may begin prior to conception or 
early in pregnancy. The endometrium can harbor 
commensal/low pathogenic organisms prior to preg-
nancy that could contaminate the fetal compartment 
in pregnancy.6 Maternal and/or fetal inflammatory 
responses will cause preterm labor, preterm rupture 
of membranes, and possibly abruption. More than 
50% of deliveries prior to 32 weeks have an inflam-
matory association.7 Abnormalities in embryo im-
plantation and subsequent abnormalities in placental 
or uterine vascular development can result in fetal 
growth restriction, preeclampsia, and perhaps some 
idiopathic preterm labors. This poorly understood 
pathophysiology associated with severe prematu-
rity implies that the majority of very preterm de-
liveries are the result of chronic and progressive 
pregnancy abnormalities. A possible interpretation 
is that the fetus responds to the abnormal maternal-
fetal environment such that there are no “normal” 
24-week fetuses; the fetuses that are delivered at 
24 weeks are abnormal/stressed. Thus, clinicians 
who describe severely preterm infants as “normal” 
because they have no respiratory distress syn-
drome (RDS) and have adapted successfully to pre-
term birth, are actually describing abnormal 
newborns.
4.  Biological Adaptability/Plasticity
The normal 24-week-gestation infant is unlikely 
to survive if delivery occurs inadvertently. Many of 
these preterms do survive with careful neonatal 
care only because the fetus has responded to the 
adverse intrauterine environment by improving the 
maturity of the organ systems. These biological 
adaptations may have modest evolutionary survival 
values for preterms born close to term, but there 
has been no evolutionary pressure for survival of very 
Table 1  Immaturity of organs of normal fetuses at 
24 weeks’ gestation responsible for morbidity 
and mortality
Lungs About 250,000 saccules, no alveoli
 Poor microvascular development
 No surfactant
 Minimal matrix in tissue
Kidneys  Very low renal blood flow and 
 glomerular filtration
 Low sodium reabsorption
 Inability to concentrate
Gut Low digestive enzymes
 Poorly developed peristalsis
Skin Minimal cornification
 Poor barrier function
Brain Immature respiratory control
Immune system Inadequate responses to infection
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preterm infants. Focusing on the lung, the potential 
for acceptable gas exchange and pulmonary func-
tion at 24 weeks’ gestation is inconsistent with the 
description of the lungs of a normal 24-week fetus.
5.  What is Lung Immaturity/RDS?
In large clinical series, most infants with birth 
weights measuring less than 1000 g are said to have 
RDS, but that diagnosis is very imprecise and in-
cludes infants with mild initial distress and short 
exposures to low oxygen concentrations. If the 
care strategy is to intubate all very preterm in-
fants at delivery, then they will all be diagnosed 
with RDS because they are ventilated.8 If they are 
intubated and given surfactant, it is not possible 
to categorize their lung disease at birth. In a re-
cent report, and despite the initiation of mechani-
cal ventilation in more than 90% of infants with 
gestational ages of less than 28 weeks, 20% of in-
fants had very low oxygen needs and may not have 
had RDS.9 Attempts to transition infants to air 
breathing using continuous positive airway pres-
sure (CPAP) immediately following birth demon-
strated that many of these infants had no or mild 
RDS.10 In 397 somewhat larger infants (gestational 
age 27.2 ± 1.6 weeks, birth weight 1033 ± 274 g), 
54% had no or mild RDS and only 30% received sur-
factant. In this population, 94% were initially 
treated with CPAP and 80% were exposed to ante-
natal corticosteroids. Ammari et al11 demonstrated 
that 69% of infants born at 23−25 weeks’ gestation 
could be transitioned to air breathing with CPAP 
and 31% remained off mechanical ventilation.
A recently published trial reported similar ex-
periences for infants requiring respiratory assist-
ance at 5 minutes after birth who were randomized 
to intubation or CPAP.12 These infants had mean birth 
weights of 950 g and gestations of 250/7 to 286/7 
weeks. Of the 307 infants in the CPAP group, 46% 
were intubated by 5 days of age and only 38% re-
ceived surfactant. There are no good data for 24-
week preterm infants. However, if these infants are 
not intubated in the delivery room, many of them 
will breathe on their own, and initially oxygenate 
with low supplemental oxygen concentrations.11 
These 24-week preterm infants often require intu-
bation during the first days of life due to progres-
sion of RDS or lack of adequate respiratory drive. 
All infants require some surfactant for initial suc-
cessful breathing, but in those that develop pro-
gressive RDS, the small amount of surfactant is 
inactivated by proteinaceous pulmonary edema.13 
One possible interpretation of this clinical experi-
ence is that most very preterm infants that we see 
as clinicians are not normal, because they do have 
some surfactant, and many have enough surfactant 
to prevent severe RDS. The infants that do develop 
RDS respond to surfactant treatment, demonstrat-
ing empirically that the saccular lung is as depend-
ent on surfactant as the alveolarized lung is. Term 
mice with saccular lungs and surfactant deficiency 
due to surfactant protein B deficiency soon die of 
respiratory distress.14
The clinical experience of infants with RDS re-
sponding to surfactant treatment demonstrates 
the inducibility of the surfactant system in se-
verely preterm infants. Little information is avail-
able, however, about alterations in lung structure 
in response to the fetal environment in these pre-
term infants. Structural information has not been 
reported because the lungs of the newborns must 
be carefully prepared and there has not been good 
quality tissue from newborns without ventilatory 
interventions for structural studies. The definition 
of lung immaturity/RDS has thus become clouded 
in these very preterm infants because of the fre-
quent occurrence of infection/inflammation and 
the ease with which these delicate lungs can be 
injured by assisted ventilation.
6.  Which Clinical Associations Improve 
Survival?
My impression is that the stimulus to survival is the 
abnormality or series of abnormalities that result 
in the preterm delivery at 24 weeks. As noted above, 
these abnormalities seem to group as either in-
flammatory or vascular development.5 There is 
some information about the effects of inflamma-
tion on the fetal lung. The prolonged rupture of 
membranes in preterm pregnancies—a surrogate for 
chorioamnionitis—has been found for many years to 
decrease the risk of RDS. In recent years, epidemi-
ological studies have associated chorioamnionitis 
with a decrease in RDS,15 although this association 
is inconsistent.16 Similarly, chorioamnionitis has been 
thought to contribute to bronchopulmonary dyspla-
sia (BPD) because it initiates lung inflammation in 
the fetus.17 The clinical data are confounded by 
the imprecise characterization of chorioamnionitis. 
For example, chorioamnionitis can be defined by 
clinical symptomatology, histology, measurements of 
inflammatory mediators or the presence of organ-
isms in the amniotic fluid. However, these defini-
tions do not identify the organisms, characterize the 
duration of fetal exposure to them, or quantify the 
location or intensity of the exposure or the fetal 
responses. The imprecise characterization of chori-
oamnionitis has also been illustrated by the different 
correlations found between RDS and BPD, and chori-
oamnionitis as defined by histology or fetal exposure 
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to Ureaplasma in a cohort of infants (Table 215,18). 
Histologic chorioamnionitis in this population of 446 
preterm deliveries at less than 32 weeks’ gestation 
predicted less RDS and no change in BPD.15 In con-
trast, infants with Ureaplasma or Mycoplasma grown 
from cord blood had less BPD, but a similar incidence 
of RDS to culture-negative infants.18 There are many 
types of chorioamnionitis and fetal responses. How-
ever, the present classification that places them 
together for outcome studies only confounds our 
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Figure 1 Responses of preterm lambs to intra-amniotic 
endotoxin [lipopolysaccharide (LPS), 10 mg] given at inter-
vals from 1 to 15 days prior to preterm delivery at 125 
days’ gestation. The lambs were ventilated for 30 minutes 
after birth. (A) Oxygenation, (B) compliance, and (C) gas 
exchange as measured by the ventilation efficiency index 
increased progressively with intra-amniotic LPS exposure. 
Redrawn from Reference 21.
Table 2   Comparison of outcomes for same cohort of 
patients in Alabama Preterm Birth Study15,18
RDS
 Histologic chorio 61% 73% *
 Blood culture positive for 66% 65% −
  Up or Mh
BPD
 Histologic chorio 7% 9% −
 Blood culture positive for 27% 10% *
  Up or Mh
*p < 0.05. RDS = respiratory distress syndrome; chorio = chori-
oamnionitis; Up = Ureaplasma; Mh = Mycoplasma hominus; 
BPD = bronchopulmonary dysplasia.
understanding of the basic processes that modulate 
fetal status at very preterm delivery.
Responses to infection/inflammation have been 
investigated in fetal sheep in order to evaluate con-
trolled exposures to inflammation. The results are 
found to be both surprising and complex. A previous 
study in rabbits found that intra-amniotic injection 
of interleukin-1 into the amniotic fluid of rabbits in-
duced lung maturation.19 In our studies, we found 
that intra-amniotic injection of Escherichia coli li-
popolysaccharide (LPS), sheep recombinant inter-
leukin-1, or live Ureaplasma parvum caused not only 
chorioamnionitis and lung inflammation, but also po-
tent and consistent lung maturation.20−22 The lung 
maturation was characterized by large increases in 
surfactant lipids and proteins, increased lung gas vol-
umes due to the structural maturation of the lungs, 
and improved gas exchange with mechanical ventila-
tion (Figure 121). Chronic colonization of the fetal 
lung with Ureaplasma from 53% of gestation resulted 
in lung maturation 70 days later following preterm 
delivery at 83% of gestation.22 Of particular note was 
that lung maturation occurred despite continued in-
flammation and Ureaplasma colonization of the fetal 
lung (Table 3). The results from these experimental 
models demonstrate that inflammation/infection 
Lung maturation and VLBW survival 11
can induce lung maturation of fetus, and support the 
idea that many very preterm infants produce some 
surfactant and have structurally more mature lungs 
due to fetal exposure to inflammation.
Abnormal uterine/placental vascular develop-
ment is another cause of prematurity that also puts 
stress on the fetus. Preeclampsia and vascular ab-
normalities of the placenta cause intrauterine growth 
restriction, although studies with large samples have 
found no decrease in the incidence of RDS in this 
group relative to that of other preterms of the same 
gestational age.23 However, this comparison was 
limited by the fact that the population also con-
tained infants exposed to inflammation. Thus, the 
results from these studies only demonstrated that 
the vascular developmental abnormalities stressed 
premature fetuses in a similar manner to the rest of 
the abnormal population. There was no comparison 
group of “normal” fetuses delivered at 24 weeks’ 
gestation. The survival of these very preterm in-
fants depended on the fetal responses to abnormal 
pregnancy events.
7.  Corticosteroids and Very Preterm 
Infants
Corticosteroids are indicated for all women at risk 
of delivering preterm infants at a viable gesta-
tional age, which is 24 weeks in the current review. 
However, this indication is extrapolated from clini-
cal experiences, as data from randomized control-
led trials include very few infants with gestations 
at delivery earlier than 28 weeks.24 Nevertheless, 
the epidemiologic data regarding the benefits of 
maternal corticosteroid treatment are compelling 
and include decreased incidences of death and RDS, 
and less risk of intraventricular hemorrhage. Results 
from animal studies have been reliable. As well, 
some clinical data have demonstrated the beneficial 
effects of antenatal corticosteroids on all the fetal 
organs listed in Table 1. Thus, corticosteroids ap-
pear to have pleiotropic effects on the overall fetal 
preparedness for very preterm births. Presently, 
about 80% of women at high risk for preterm delivery 
receive corticosteroids.
A component to the miracle of very preterm 
survival is the additive or synergistic effects of ma-
ternal corticosteroid treatments on other factors 
that improve survival. In our experimental work 
with fetal sheep, for example, the maternal corti-
costeroid treatment on lung maturation induced by 
intraamniotic LPS was found to have beneficial ef-
fects, and corticosteroid-exposed fetal sheep or 
humans also showed improved responses to post-
natal surfactant treatment.25,26 The effects of an-
tenatal corticosteroids administered simultaneously 
with intra-amniotic LPS to fetal sheep were approxi-
mately additive in increasing the amount of sur-
factant, improving static lung gas volume and 
improving dynamic compliance (Figure 227).
Antenatal corticosteroids have acute effects on 
preterm fetal sheep lungs, including decreased 
edema formation, increased lung gas volume, 
and improved fluid clearance after birth. The 
corticosteroid-exposed fetal lung responds to sur-
factant treatment with a further increase in lung 
gas volume, with less inhibition of surfactant by 
proteins in pulmonary edema, and a lower dose of 
surfactant required to improve lung function (a 
change in the surfactant dose-response curve).2 
The net effect is improved lung function. These 
integrated responses to the combination of antena-
tal corticosteroids and postnatal surfactant cannot 
be directly tested in humans. However, in nonran-
domized observations, infants exposed to antena-
tal corticosteroids and then randomized to 
surfactant showed less pneumothorax and lower 
mortality than surfactant-treated infants not 
exposed to corticosteroids.28
Table 3  Comparison of lung maturation and inflammation at 125 days’ gestation between Ureaplasma parvum-
exposed lambs (intra-amniotic Ureaplasma at 80 days’ gestation) and vehicle-exposed controls
 Ureaplasma Control p
Animals (n) 9 9 −
Indications of inflammation
 White cells in cord blood (×109/L) 2.7 ± 0.4 4.1 ± 0.5  0.03
 Inflammatory cells in alveolar wash (×104/kg) 350.0 ± 140.0 0.9 ± 0.8 < 0.01
 IL-8 protein in alveolar wash (μg/mL) 53.0 ± 9.0 Not detected < 0.01
Indications of lung maturation
 Lung gas volume at 40 cmH2O pressure (mL/kg) 19.7 ± 3.3 7.1 ± 0.8 < 0.01
 Saturated phosphatidylcholine (μmol/kg) 0.8 ± 0.2 0.07 ± 0.02 < 0.01
 Surfactant protein B (relative to control) 19.0 ± 3.0 1.0 ± 0.4 < 0.01
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8. Lung Injury
Other factors implicated in the survival of these 
very preterm infants are under the control of the 
clinicians providing care. Neonatologists have de-
veloped effective ways to control temperature, ad-
minister fluids and nutrition, and to close patent 
ductus arteriosus. The newer approaches to venti-
lation management may also contribute significantly 
to survival. Clinicians are less aggressive in trying 
to optimize ventilation and do less monitoring with 
invasive catheters in these infants. The use of CPAP 
to encourage spontaneous breathing, and minimize 
intubation and mechanical ventilation can decrease 
the risks of lung injury. However, these more 
“hands-off” approaches to clinical care would not 
be possible if the fetus was not prepared for the 
preterm birth by the antecedent abnormalities of 
the pregnancy.
9.  Conclusion
The survival miracle of very low birth weight infants 
has more to do with the biology of prematurity 
than with the skill of the clinician. Very preterm 
birth is, in fact, a very abnormal and relatively in-
frequent (< 1%) event in human reproduction. These 
infants have survived a potentially long period of 
intrauterine abnormalities and have made a number 
of organ adaptations that fortuitously aid their sur-
vival with careful clinical management. This survival 
is further aided by clinical interventions, antenatal 
corticosteroids, postnatal surfactant, and gentle 
handling and ventilation.
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